-

Shareholder Alert: Robbins LLP Reminds Investors Health Insurance Innovations, Inc. (HIIQ) Sued for Misleading Shareholders

SAN DIEGO & TAMPA, Fla.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Health Insurance Innovations, Inc. (NASDAQ: HIIQ) filed a derivative complaint against the company's officers and directors for alleged breaches of fiduciary duties and gross mismanagement. Health Insurance Innovations, Inc. operates a cloud-based technology platform and is a distributor of individual and family health insurance plans.

If you suffered a loss as a result of HIIQ's misconduct, click here.

Health Insurance Innovations, Inc. (HIIQ) Accused of Misleading Investors

According to the complaint, HIIQ filed its Florida third-party administrator ("TPA") application in July 2016, which HIIQ needed to operate its core business. While HIIQ was in its application process, the company was under investigation for allegedly fraudulent business practices in 42 states. HIIQ's Florida TPA application was denied in June 2017, due to material errors and omissions, including the omission that two of its officers had been named in lawsuits "involving dishonesty, breach of trust or a financial dispute." HIIQ concealed the denial until it filed its August 4, 2017 Form 10-Q, which failed to disclose the necessity of obtaining a TPA license and deliberately understated the potentially devastating consequences the denial would have on company operations. Then, in September 2017, Seeking Alpha released an article revealing the disastrous "domino effect" the TPA denial caused, including loss of additional licenses. On this news, the share price declined by 37%, closing at $19.75, and has yet to recover.

Health Insurance Innovations, Inc. (HIIQ) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leonid Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:HIIQ

Release Versions
$Cashtags

Contacts

Leonid Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom